

Waisman Biomanufacturing Completes Initial Transfer of RoosterBio Manufacturing Processes

Madison, WI, August 19, 2024 - Waisman Biomanufacturing, a leading contract development and manufacturing organization (CDMO) which is strategically part of the University of Wisconsin Madison, previously announced a strategic partnership with RoosterBio, Inc., a leading provider of human mesenchymal stem/stromal cells (MSCs), highly engineered media solutions, and bioprocess development services.

Following up that [initial announcement](#), Waisman Biomanufacturing executed RoosterBio's representative manufacturing scale 2D manufacturing processes for bone-marrow derived MSC expansion and conditioned media harvest for exosome processing and characterization. Waisman also bridged its validated aseptic fill capabilities utilizing an automated fill line into AT-closed vials ready for vapor phase liquid nitrogen storage.

Quality Control testing was performed by both RoosterBio and Waisman to bridge results. Cell viability was similar in both cryovial samples and AT-closed vial samples. Likewise, the conditioned media was characterized for extracellular vesicle content for total protein concentration, EV concentration and sizing, as well as surface and cytosolic markers CD9, CD63, CD81, and TSG101.

This work marks the next stage in Waisman Biomanufacturing and RoosterBio delivering an end-to-end solution for the development and manufacturing of cell- and exosome-based therapeutics, including the critical raw materials, expert process development in both 2D and 3D systems, advanced analytical characterization, regulatory support packages, and proven cGMP manufacturing capabilities. Advanced therapy developers in both industry and academia can now accelerate and de-risk their progression into clinical trials by leveraging this new strategic collaboration.

Christopher Bartley, Managing Director of Waisman Biomanufacturing, expressed his excitement for this data: "We were thrilled to partner with RoosterBio back in February, and were excited to see the preliminary data after initial tech transfer of RoosterBio's processes. We look forward to additional collaborations with product developers and academic investigators to advance MSC and EV programs to the clinic."

About Waisman Biomanufacturing

With its state-of-art production facility in Madison, WI, and its expert personnel, Waisman Biomanufacturing has become a leading GMP CDMO which manufactures a wide range of biotherapeutics for clinical trials. The products include gene therapies, cell therapeutics, and both therapeutic and prophylactic vaccines. More information is available at: <https://gmpbio.org>.

About RoosterBio

RoosterBio accelerates human mesenchymal stem/stromal cell (hMSC) and extracellular vesicle (EV) product and process development to fuel the rapid implementation of scalable advanced therapies. Our high-quality hMSCs, bioprocess media, genetic engineering tools, and EV production solutions are paired with expert bioprocessing knowledge to progress therapeutic developers from concept to first-in-human testing and commercial manufacturing at reduced cost and increased productivity. With optimized, scalable processes, Type 2 Master Files, and cGMP products, we have enabled therapeutic programs to

traverse their path to clinical translation in under 1 year. RoosterBio is driven by clients' success and creating a world where safe and effective regenerative medicines are rapidly developed and widely available on a global scale.